Literature DB >> 3967454

Absolute bioavailability of amiodarone in normal subjects.

S Pourbaix, Y Berger, J P Desager, M Pacco, C Harvengt.   

Abstract

The relative and absolute bioavailability of different oral forms of amiodarone was examined in 12 subjects. The doses were 5 mg/kg iv, two 200-mg commercial tablets by mouth, two 200-mg tablets (new formulation) by mouth, and 400 mg in a drinkable solution. Plasma levels of amiodarone and its N-desethylated metabolite were determined by HPLC. Statistical analysis indicated bioequivalence of the oral forms for all the kinetic parameters examined. After oral dosing, amiodarone was slowly absorbed and the maximum plasma level (0.55 +/- 0.20 mg/l) was reached in 4.5 hr. The absolute bioavailability of oral amiodarone was calculated by comparison of AUCs after oral dosing with those after intravenous injection. A mean oral bioavailability of 65% +/- 22% was indicated. Since the tablets were bioequivalent to the drinkable solution, incomplete absorption seems not be a result of the dissolution characteristics of the commercial formulation but rather of a first-pass effect.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3967454     DOI: 10.1038/clpt.1985.22

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.

Authors:  Jiekun Xuan; Si Chen; Baitang Ning; William H Tolleson; Lei Guo
Journal:  Chem Biol Interact       Date:  2015-10-22       Impact factor: 5.192

Review 3.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

4.  Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart.

Authors:  P Chatelain; L Meysmans; J R Mattéazzi; P Beaufort; M Clinet
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 5.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 6.  New antiarrhythmic drugs in pediatric use: amiodarone.

Authors:  T Paul; P Guccione
Journal:  Pediatr Cardiol       Date:  1994 May-Jun       Impact factor: 1.655

7.  Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias.

Authors:  Joe-Elie Salem; Maria El-Aissaoui; Margaux Alazard; Jean-Sébastien Hulot; Nadia Aissaoui; Jean-Yves Le-Heuzey; Christian Funck-Brentano; Christophe Faisy; Saik Urien
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

8.  Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumour cells.

Authors:  B Chauffert; D Rey; B Coudert; M Dumas; F Martin
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

9.  Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease.

Authors:  Catherine C Bell; Delilah F G Hendriks; Sabrina M L Moro; Ewa Ellis; Joanne Walsh; Anna Renblom; Lisa Fredriksson Puigvert; Anita C A Dankers; Frank Jacobs; Jan Snoeys; Rowena L Sison-Young; Rosalind E Jenkins; Åsa Nordling; Souren Mkrtchian; B Kevin Park; Neil R Kitteringham; Christopher E P Goldring; Volker M Lauschke; Magnus Ingelman-Sundberg
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

10.  A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity.

Authors:  Rowena L Sison-Young; Volker M Lauschke; Esther Johann; Eliane Alexandre; Sébastien Antherieu; Hélène Aerts; Helga H J Gerets; Gilles Labbe; Delphine Hoët; Martina Dorau; Christopher A Schofield; Cerys A Lovatt; Julie C Holder; Simone H Stahl; Lysiane Richert; Neil R Kitteringham; Robert P Jones; Mohamed Elmasry; Richard J Weaver; Philip G Hewitt; Magnus Ingelman-Sundberg; Chris E Goldring; B Kevin Park
Journal:  Arch Toxicol       Date:  2016-06-25       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.